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Abstract: Precision medicine aims to provide the precise treatment for the patient with the right dose at the right point 
of time. Biomarkers (BM) are vital for the identification of patients who would benefit the most from individualized 
treatment. In addition, they help to enable the prediction of prognosis, the detection of early therapeutic and adverse 
effects, and may serve as surrogate endpoints in clinical trials. BM are becoming essential tools to increase productivity 
in drug discovery and impressively enhance the way medicine is practiced. However, the identification, sufficient vali-
dation and implementation of such BM are challenging. This process requires expertise from different areas and high 
resource investments. Collaborations of different partners may be helpful to overcome these challenges. In the past 
decade, collaborations between diagnostics and pharmaceutical companies as well as industrial–academic collabora-
tions have been increasingly pursued. Moreover, public funding may offer support and open new opportunities to form 
such consortia. Herein we give an overview of the different types of collaborations, their opportunities and challenges, 
and describe experiences in forming strategic partnerships with other companies. 
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Introduction 
recision medicine aims to treat diseases with 
consideration for individual biological variabil-
ity. It represents one of the most important 
trends in medicine[1]. Owing to biological variability, 
often only a subset of patients may benefit from a par-
ticular therapy. Thereby, biomarkers (BM) are essen-
tial tools required to predict therapeutic responses as  
well as to facilitate the selection of appropriate pa-
tients for treatment with certain drugs. Despite the 
major progress in drug discovery, the research and 
development costs to launch new drugs has increased 
dramatically over the last decade exceeding more than 
1 billion € per new drug. The number of Food and 
Drug Administration (FDA) approved drugs per bil-
lion US dollars of research and development spending 
has decreased by 50% approximately every nine years 
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(Figure 1). This indicates a productivity gap[2]. It is 
not a sustainable process and one that ought to be fur-
ther evaluated. One of the main driver costs is the high 
attrition rate of drugs in the early clinical development 
phase. This is particularly challenging as many drugs 
fail rather late in their development after many years 
of multimillion-dollar investments. Success rates in 
phase II studies, studies describing the first applica-
tion of an investigational drug to patients, have been 
historically low and have further decreased to an un-
sustainable level (Figure 2)[3]. Remarkably, the lack of 
or insufficient therapeutic effects is the main reason 
for failure at the present time.  
It should be noted that the application of a ‘BM 
stratified approach’ referring to drugs that are ap-
proved for particular patients’ subgroups only, would 
increase the success of clinical testing. Vice versa, 
applying a non-BM stratified population, the propor-
tion of successful selected patients would decrease, 
since the ‘dilutive effect’ of patients not suited for a 
precision therapy would have resulted in a negative 
outcome of the study even in case of a tremendous 
response rate in a small subgroup. Thus BM are effec-
tive tools to reduce attrition rates and companies 
started to invest significant efforts and money into the 
development of precision medicine. Because of its use 
to predict prognosis and detect early therapeutic and 
adverse events, the impact of BM is significant. Also 
BM may serve as surrogate markers for clinical end-
points, shortening the product development period and 
saving costs. As a consequence, BM are of increasing 
importance in medicine and drug discovery[1,4]. 
 
 
 
Figure 1. Decline of productivity in the pharmaceutical industry. 
The number of FDA approved drugs per billion US dollars of R&D spending has halved approximately every nine years. Figure reproduced from: 
Scannell J W, Blanckley A, Boldon H, et al. 2012[2]. Published with approval by Nature.  
 
 
 
Figure 2. Increasing phase II failures. 
Success rates for new development projects in phase II have fallen 
from 28% to 18%, with insufficient efficacy as the most frequent rea-
son. The 108 failures are divided according to (A) reason for failure 
when reported (87 drugs) and (B) therapeutic area. Figure reproduced 
from: John Arrowsmith, 2011[3]. Published with approval by Nature.  
Need for Collaboration: Opportunities and 
Challenges  
Developing BM is challenging and expensive. Two 
elements are required for the successful BM estab-
lishment: 
(i) The sufficiently validated BM. This includes a 
measurable parameter and a qualified assay for its 
detection. Usually the required expertise exists only 
within dedicated groups in academia or in the phar-
maceutical companies, rather than at a single institu-
tion. This is not surprising since it requires a substan-
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tiated understanding of disease pathophysiology, the 
particular pathway targeted, and the mode of action of 
the compound. 
(ii) The expertise to develop and market diagnostic 
tests. 
Table 1
This is not linked to academia or to pharma 
companies alone. Most pharma companies separated 
their diagnostic business. Roche is probably a rare 
exception still running its own diagnostic business. In 
contrast, such knowledge is well established in the 
diagnostic industry which in turn lacks the other ex-
pertise described and usually does not have the capac-
ity to establish BM on its own. This is particularly true 
if it is intended to be used to support a drug not yet on 
the market. For stratification biomarkers regulatory 
agencies strongly suggest it is essential that the drug 
and the BM are developed together from early on us-
ing a simultaneous model with the end result being a 
‘companion diagnostic’. BM validation requires ex-
tensive testing of clinical samples, i.e., access to 
well-defined patient samples which are usually best 
provided by experienced clinical academic groups. 
Therefore it is obvious that collaboration between 
academia and different partners from the pharmaceut-
ical and diagnostic industries with complementary 
skills may be beneficial and are needed.  sum-
marizes the strengths of the various types of partners. 
Figure 3 shows different kinds of collaborations. 
Partnerships are well suited for competitive research 
with ‘intellectual property generation’ and the short- 
to mid-term need for complementary competencies. 
Consortia seem to be most attractive for work in 
pre-competitive areas, with long-term interest which 
shape the environment. These two categories of col-
laborations are within the main scope of this review. 
Further ‘traditional’ well established collaborations 
with key opinion leaders and fee-for-service collabo-
rations are not specifically discussed in this paper. 
Since the business models of pharmaceutical and 
diagnostic industries are different, specific cooperation 
challenges are formed. Typically the pharmaceutical 
industry works with high risk development costs, long 
development duration and high rewards. For the di-
agnostic industry a contrasting scenario is depicted. 
Comparably low risk development, low costs, and 
short development duration, but with lower financial 
reward. A consequence for diagnostic companies is 
that it is not rewarding to invest into the development 
of BM on their own due to high costs caused by regu-
latory requirements and uncertain recapture of in-
vestments. The possibility of drug development failure 
is high.  
It is well known that more than 90% of drug deve-
lopments fail at the start of clinical investigation. If a 
diagnostic test is successfully developed in parallel it 
is more likely that the diagnostic company will end up 
with a viable product that can be sold with the drug.  
 
Table 1. Strengths of partners involved into BM collaboration 
Partner Core competence and strengths 
Academia 
Access to well defined patient material 
In-depth pathophysiological understanding of target diseases and pathways 
Innovative ideas for novel targets, biomarkers, assays, and technologies  
Pharmaceutical industry 
Drug discovery skills 
Expert knowledge regards the development compound 
Regulatory expertise for drug development 
Diagnostic industry  
Diagnostic assay development and marketing skills 
Access to novel assay technologies 
Regulatory expertise for assay development  
 
Consortia 
• pre-competitive 
• long-term interest 
• shaping the environment 
Alliances/Partnerships 
• competitive research 
• intellectual property generation 
• short- to mid-term interest 
• need for complementary 
competencies from partner 
Fee-for-Service 
• clearly defined task 
• no intellectual property generation 
• short-term interest 
 
Figure 3. Different kinds of pharmaceutical collaborations. 
Key elements of the particular categories of collaborations are shown. Different collaborations can be applied and combined for particular projects.  
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Moreover, profits for diagnostics usually result from 
high volume testing. However, this does not apply to 
small populations such as specific types of cancer pa-
tients who are tested only once for the purpose of drug 
stratification. Finally, the prices for diagnostic tests 
are set by the technology (e.g. dependent whether its 
immunohistological, PCR based etc.) and not val-
ue based. This ignores the higher development costs 
for companion diagnostics which makes it more un-
appealing for diagnostic companies to invest in strati-
fication BM on their own without additional incen-
tives. There is a high need for common calculation, 
and cost and risk management between pharmaceuti-
cal and diagnostic partners. Pharmaceutical companies 
tend to stimulate and support BM development activi-
ties in diagnostic companies either by paying for the 
BM development costs or paying a premium for 
access to an available companion diagnostic. An ad-
vantage of working on a project-to-project basis is the 
given flexibility. However, for the pharmaceutical 
company, investment costs may rise if there is an in-
crease in demand and competition from other pharma 
companies due to the possible limitations of diagnos-
tic development capacities. Strategic partnerships 
create an opportunity to overcome the majority of 
these challenges. 
The idea of a strategic partnership includes a sig-
nificant commitment for the long-term, sometimes 
even an exclusive collaboration between two or more 
partners with complementary strengths. Another poss-
ible collaboration opportunity is to form large consor-
tia. In addition to bringing together complementary 
expertise, it also helps to share significant costs.  In 
the case of establishing surrogate BM many compa-
nies would stand to benefit, in contrast to individual 
drugs which only benefit a few. Providing public 
funding for consortia could be particularly interesting 
as this appears to be an increasingly popular new trend.  
Partnerships Between Diagnostic and Phar-
maceutical Companies 
In the ‘biomarker arena’ partnerships between two or 
more pharmaceutical companies with individual di-
agnostic divisions are well established. These rela-
tionships allow for the development of companion 
diagnostics, which are essential for patient stratifica-
tion biomarkers. In the era of precision medicine most 
pharma companies have decided to use the compe-
tence and expertise of the diagnostic companies rather 
than to build up in house-diagnostic development ca-
pabilities themselves. At the same time, guaranteed 
assay development slot and pricing structures are 
thought to be important and secured by forming such 
relationships. For the diagnostic companies in turn it 
provides stability by securing a significant number of 
projects leading to a more continuous and reliable 
workflow. For both partners the administrative work-
load to enter and manage the collaboration decreases 
over time due to the learning curve. Oftentimes aca-
demic partners do not enter such core collaborations. 
However, they can become crucially involved if novel 
technologies are necessary or a marker needs to be 
evaluated in larger patient populations.  
The Partnership Between Bayer and Ventana 
Bayer established several partnerships in order to de- 
velop companion diagnostics with experts that have 
proven experience with developing and commercia-
lizing companion diagnostics (Ventana and Qiagen). 
Bayer also established one partnership with a company 
that had an innovative novel technology platform 
(Sysmex Inostics) as shown in Table 2. 
Following in line with other pharmaceutical com-
panies, Bayer has been successful at developing Anti-
body Drug Conjugates (ADC) against novel oncology 
targets. Immunohistochemical (IHC) assays are usually 
used to select patients that should receive the ADC. 
Considering that there are only three IHC diagnostic 
manufacturers with limited development capacities, 
Bayer decided to align with Ventana. The advantage of 
this strategic partnership was the robust prototype IHC 
assay that was implemented and used in the early 
phase I studies. It was evaluated for the use as a com-
panion diagnostic, the test that would be required for 
pivotal registration trials and drug submission. Using 
this approach was helpful to limit the risk of failure in  
 
 
 
Table 2. Established partnerships of Bayer to develop companion diagnostics 
Partner Technology Portfolio relevance 
Ventana Immunohistochemistry FISH (Over)expression necessary for drug action in multiple projects 
Qiagen Mutational Analysis Tissue Tumor driver mutation targeted by compound or downstream of target 
Sysmex/ Inostics Blood based Mutational analysis Tissue difficult to access/Screening for low mutation frequency 
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the clinical drug development program, since the an-
tibody assay would have shown early in the develop-
ment phase critical points. 
The partnership was established at the phase I stu-
dies. Both teams had the opportunity to learn crucial 
steps needed to co-develop an IHC diagnostic assay 
along with the ADC. A key element for success was to 
align as early as possible on the diagnostic and drug 
development strategies. This was because regulatory 
agencies within different countries have different ap-
proval timelines, which can dramatically delay clinical 
trials and start times. Moreover, regulatory interac-
tions require communication with different FDA de-
partments: Center for Devices and Radiological 
Health (CDRH) for the medical device and Center for 
Drug Evaluation and Research (CDER) and Center for 
Biologics Evaluation and Research (CBER) for Bi-
ologics License applications. The different depart-
ments have their own standards. By aligning the regu-
latory teams from Bayer and Ventana, regulatory data 
packages were more easily assembled and submitted 
in a timely manner. 
Another important advantage was the possibility to 
generate antibodies according to the specifications 
required by Ventana to perform on formalin fixed pa-
raffin embedded tissue. Ventana’s antibody manufac-
turer is aligned on the process and requirements 
needed for a sensitive and specific IHC assay. 
Collectively the streamlined processes that Ventana 
offers should expedite the development of appropriate 
IHC assays that can be further developed as compa-
nion diagnostics without delays to the commercializa-
tion and launch of the pharmaceutical companies ADC.  
The Partnership Between Bayer and Qiagen 
Bayer also entered a strategic relationship with Qiagen 
to develop clinical trials assays for several early phase 
clinical programs. For Bayer the advantages of this 
partnership comprise of global penetration, the know- 
how with regards to RT-PCR tests, the regulatory ex-
pertise of Qiagen with validating kits to European CE 
and US FDA standards, and experience in filing pre-
market applications.  
By engaging early and aligning clinical develop-
ment programs, Bayer was able to identify rare sam-
ples needed for the verification and validation of the 
polymerase chain reaction (PCR) tests. When time-
lines in the clinical trial changed, Qiagen modified 
their development plans to accommodate Bayer’s 
clinical trial demands. Bayer used only one test that 
was taken to the Investigational-use-only-level and 
later stage bridging studies were not necessary.  
The knowledge that Bayer scientists gained by de-
veloping an IHC companion diagnostic assay coupled 
with the lessons learned from Qiagen were helpful for 
subjects working in the Bayer global drug discovery 
division to feel more comfortable and knowledgeable 
on implementing companion diagnostics tests ranging 
from research use only assays to investigational use 
only assays in early and pivotal clinical trials. These 
experiences have been invaluable for phase I dose 
escalation and expansion studies that require the use 
of stratifications assays.  
The Partnership Between Bayer and Sysmex-Inostics  
Several tumors shed deoxyribonucleic acid (DNA) 
into the blood stream which can be measured as cir-
culating tumor DNA (ctDNA)[5]. The detection of 
ctDNA offers the possibility for minimally invasive 
testing and the ability to study the mutational status of 
a tumor. Compared to invasive biopsy sampling pro-
cedure this is associated with lower risk for patients. It 
allows for the testing of patients who do not have ac-
cessible tumors which can be biopsied. This also al-
lows for the detection of resistance through conti-
nuous monitoring of the mutational status of tumors 
during the therapy. One may also speculate whether 
this method represents a more holistic readout of the 
mutational tumor status, especially in a metastatic set-
ting, than a single biopsy from a potentially non-rep-
resentative part of the primary neoplasia. 
In order to detect minute amounts of ctDNA in bl-
ood a highly sensitive technology platform is neces-
sary. The BEAMing technology platform offered by 
Sysmex-Inostics provides such a platform[6]. Initially 
the partnership was intended to establish a regulatory 
pathway with the FDA and to validate the platform 
ready to use for prospective patient selection as there 
are no FDA approved companion diagnostics based on 
the BEAMing technology. The BEAMing technology 
was successfully implemented in a global prospective 
study to screen for patients with a certain mutational 
status in a tumor indication where sampling inva-
sive biopsies would have a high risk of bleeding. Fur-
thermore, several studies conducted with the use of 
BEAMing compared the two technologies: the ctDNA 
mutational status and the mutational status detected 
via conventional PCR methodologies in tumor tissue.  
Entering into a strategic partnership with Sysmex- 
Inostics revealed several challenges. Some of the 
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challenges were the lack of regulatory experience re-
quiring the use of external regulatory consultants at 
times and working through the growth and establish-
ment process of the company respectively. Advantages 
of working with smaller companies are due to their 
higher flexibility to shape the technology implementa-
tion strategy and to match clinical development time-
lines and needs. Overall the partnership was successful. 
The FDA was shown the value through a combination 
of new technology coupled with clinical data which 
allowed them to work closely with Sysmex Inostics. 
Partnerships Between Academia and Industry 
Collaborations between academic institutions and the 
diagnostics and pharmaceutical industry are increa-
singly initiated and executed. It is assumed that these 
relationships could help to improve research and de-
velopment productivity in the industry, as well as ena-
ble academic institutions to better exploit the transla-
tional potential of their research[7]. 
The Partnership Between Bayer and the German 
Cancer Research Center 
In 2009, Bayer and the German Cancer Research 
Center (DKFZ) joined forces in a strategic partnership 
along the entire drug discovery and early development 
value chain. Since then this partnership has resulted in 
30 joint projects, mainly in the area of target discovery 
and validation. More than half of them have already 
achieved milestones on lead discovery or optimization. 
In 2013 both partners decided to extend their collabo-
ration with a joint laboratory for immunotherapies at 
the National Center for Tumor Diseases in Heidel-
berg[8]. This strategic partnership based on positive 
experiences has led to a better understanding of rele-
vant pathways in a number of cancers and to nov-
el biomarker candidates with the potential to support 
patient stratification in specific indication areas. Key 
success factors for this partnership are long-term col-
laboration on an equal scientific level with close inte-
raction and exchange of expertise resulting in mu-
tual benefit. An efficient process has been achieved 
with a framework of agreement enabling the quick 
setup of joint projects, based on a short joint decision 
process and without additional single project negotia-
tions. This enables scientists involved from both sides 
to translate their research into application.  
Science Hubs — Fostering Interactions Through 
Co-localization  
Another approach to promote the interaction between 
industry, academia and start-ups are science hubs and 
incubators. Bayer was the first company establishing 
an Innovation Center next to the University of Cali-
fornia, San Francisco in Mission Bay. Furthermore, 
Bayer established an Incubator — a so-called “CoLa-
borator” for start-ups offering space and expertise. 
This model has proven to be very successful as a 
number of new partnerships evolved over time. The 
co-localization of scientists facilitates close interaction 
and informal exchange. Recently, this project was ex-
tended to Bayer facilities in Berlin, where young bio-
tech start-ups are hosted.  
Other Examples 
Other examples for Bayer collaborative efforts are the 
Grants for targets initiative and a compound provision 
program, which we reviewed elsewhere[9–11].  
Consortia Supported by Public Funding 
Significant public funding has become available for 
biomarker research in the past years. Public-private- 
partnerships like the Innovative Medicines Initiative, 
the FDA-Biomarker-Consortium and others, as shown 
in Table 3, offer the opportunity to create critical mass 
consortia of excellent partners in specific areas. In 
most cases, multiple companies and academic institu-
tions join forces to address an issue which would be 
difficult to address by only one participant alone. Re-
cently these approaches have been reviewed[12]. 
Examples include the pooling of resources to deci-
pher the molecular basis of complex diseases such as 
diabetes, resulting in better safety and efficacy mark-
ers (www.imi-summit.eu). Similarly, novel approaches 
like systems medicine for the identification of nov-
el biomarker patterns with potential for patient strati-
fication may be tested. One of these successful exam-
ples is the Innovative Medicines Initiative project On-
coTrack, where more than 200 colon cancer patients 
were analyzed in a novel modelling system using data 
from next generation sequencing and methylome 
analysis (www.oncotrack.eu). The recently constituted 
Innovative Medicines Initiative consortium CANCER- 
ID (www.cancer-id.eu) aims to evaluate the clinical 
utility of different technologies for enrichment, isola-
tion and analysis of circulating tumor cells, circulating 
free tumor DNA, and microRNAs.  
These biomarkers serve the concept of ‘liquid bi-
opsy’ which may allow for longitudinal sampling 
when standard biopsies are not available or pose a 
significant risk to the patient. The 36 European and  
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Table 3. Current examples of Biomarker Consortia, supported by public funding in Europe and the United States  
Name Country /  Main participants Disease areas Link 
IMI Several member sta-
tes within the EU  
Broad indication coverage, e.g. T2 Diabetes 
(IMIDIA, SUMMIT, DIRECT), AD (Phar-
ma-Cog), Asthma (U-BIOPRED), Oncology (On-
coTrack, Cancer-ID), Autism (EUAIMS), Drug 
Safety (SAFE-T, MIP-DILI, MARCAR) Vaccine 
Safety (BioVacSafe) 
www.imi.europa.eu 
HORIZON 2020 Several member sta-
tes within the EU 
Various programs, e.g. breast cancer http://ec.europa.eu/programmes/horizon2020/ 
Dutch Biomarker De-
velopment Center 
The Netherlands  COPD, Type2 Diabetes, Alzheimer’s Disease http://www.biomarkerdevelopmentcenter.nl/ 
EATRIS-ERIC Several member sta-
tes within the EU 
Cross indication, focus on infrastructure for trans-
lational medicine 
http://www.eatris.eu/ 
BBMRI-ERIC Several member sta-
tes within the EU 
Cross indication, focus on infrastructure of bio-
banks and biomolecular resources 
http://bbmri-eric.eu/ 
Biomarker Consortium US (FDA, industry) Broad indication coverage http://www.biomarkersconsortium.org/ 
BIQSFP US (NCI) Cancer: Biomarker, Imaging and Quality of Life 
Studies Funding Program (BIQSFP) 
http://www.cancer.gov/aboutnci/organization/
ccct/other-programs/biqsfp 
Parkinson’s Disease Bi-
omarker Program 
US (NINDS) Parkinson’s Disease https://pdbp.ninds.nih.gov/ 
Modified after Asadullah K, Busch A, Gottwald G, et al. 2015 (supplement)[12]. Published with approval by Nature. 
 
 
US CANCER-ID partners are now working on:  
(i) defining standards for circulating tumor cell 
identification and counting, and  
(ii) standard operating procedures for pre-analytical 
sample handling and analyses.  
The European consortium, Biomarker-Driven Im-
munosuppression, is going to implement recently ide-
ntified biomarkers into the management of immuno-
suppression after solid organ transplantation. For the 
first time, in several clinical trials supported by diag-
nostic and pharma companies, biomarkers will be used 
as decision criteria to guide personalized immunosup-
pression. This would allow drug minimization or even 
weaning without harming the kidney and liver allo-
grafts. The methodical implementation of these bio-
markers is finalized. As a result up to 1,000 patients 
will be enrolled in different multi-center trials[12]. Other 
examples for successful consortia in the biomarker 
area are the Biomarkers consortium[13], the Predictive 
safety testing consortium, and the coalition against 
major diseases[14]. 
Concluding Remarks and Further Perspectives 
Collaboration between academia, diagnostic and 
pharmaceutical industry, best in consortia, is essential 
for successful biomarker discovery, development, and 
implementation as it requires high resources and com-
plementary skills[12,14]. It can be assumed that the 
number of academic-industrial collaborations will 
further increase, partly due to the increasing availabil-
ity of public funding. The current biomarker consortia 
with collaborating groups from academia, pharmaceu-
tical and diagnostic companies will probably be 
joined by information technology companies as ‘big 
data’, e.g. generated by whole genome analyses, needs 
to be analysed. Involvement of young academic 
groups and biotech companies may provide access to 
highly innovative technologies. Science hubs and in-
cubators are providing a promising opportunity to 
support the activities of biotech and internet start-ups 
and bring them in close proximity to established 
pharmaceutical companies where the co-location of 
scientists facilitates intense interaction and informal 
exchange. For the exploration and clinical validation 
of a new biomarker candidate or a novel technology 
larger consortia may be appropriate[12]. Each category 
of collaboration has its own needs and challenges to 
overcome in order to be successful. Crucial factors for 
complex consortia are:  
(i) a good balance between critical mass and 
manageable size,  
(ii) involvement of both diagnostics and pharma-
ceutical industry partners,  
(iii) early alignment on the joint goals between 
public and private partners, and  
(iv) a professional project management.  
Based on our experience such consortia are essen-
tial to create the critical mass needed to achieve ac-
ceptance of surrogate biomarkers, a new technology, 
or to validate a stratification biomarker in a complex  
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Figure 4. Key success factors for partnerships (RESOLVE MODEL). 
 
 
clinical setting.  
However, people will only actively engage in col-
laboration when the benefit they derive is greater than 
the effort and time it takes to collaborate. We have 
identified key success factors for collaborations that 
are summarized in the RESOLVE Model as shown in 
Figure 4[15]. According to the model six key elements 
have to be taken into account:  
(i) good relationship management,  
(ii) clear agreement on the strategic goals of the 
partnership,  
(iii) transparent definition of processes and gov-
ernance structures (operational excellence),  
(iv) openness to learn from each other as the dif-
ferences between the partners are a key driver 
of the partnership,  
(v) open communication. and  
(vi) support from the bench and the senior man-
agement.  
In summary, collaborations that result from strate-
gic partnerships and consortia are key for success-
ful biomarker discovery and establishment. The kind 
of collaboration needs to fit to its purpose. 
Conflict of Interest and Funding 
LL and PR have no conflict of interest to declare. AB, 
PC, MG, and KA are employees and shareholders of 
Bayer AG. JR is a shareholder of Bayer AG and an 
employee of Astra Zeneca.  
References  
1. Landeck L, Kneip C, Reischl J, et al. 2015, Biomarkers 
and personalized medicine: current status and further 
perspectives with special focus on dermatology, in Ex-
perimental Dermatology. (In press) 
2. Scannell J W, Blanckley A, Boldon H, et al. 2012, Di-
agnosing the decline in pharmaceutical R&D efficiency. 
Nature Reviews Drug Discovery, vol.11: 191–200.  
3. Arrowsmith J, 2011, Phase II failures: 2008–2010. Na-
ture Reviews Drug Discovery, vol.10: 328–329. 
4. Salter H and Holland R, 2014, Biomarkers: refining di-
agnosis and expediting drug development — reality, as-
piration and the role of open innovation. Journal of In-
ternal Medicine, vol.276: 215–228. 
5. Bettegowda C, Sausen M, Leary R J, et al. 2014, Detec-
tion of circulating tumor DNA in early- and late-stage 
human malignancies. Science Translational Medicine, 
vol.6: 224. 
6. Diehl F, Li M, He Y, et al. 2006, BEAMing: sin-
gle-molecule PCR on microparticles in water-in-oil 
emulsions. Nature Methods, vol.3: 551–559.  
7. Lessl M, Bryans J S, Richards D, et al. 2011, Crowd 
sourcing in drug discovery. Nature Reviews Drug Dis-
covery, vol.10: 241–242. 
8. Wellenreuther R, Keppler D, Mumberg D, et al. 2012, 
Promoting drug discovery by collaborative innovation:  
A novel risk- and reward-sharing partnership between 
the German Cancer Research Center and Bayer Health-
Care. Drug Discovery Today, vol.17: 1242–1248. 
9. Lessl M, Schoepe S, Sommer A, et al. 2011. Grants-
4targets — an innovative approach to translate ideas 
from basic research into novel drugs. Drug Discovery 
Today, vol.16: 288–292. 
Lilla Landeck, Monika Lessl, Joachim Reisch, et al. 
 
 Advances in Precision Medicine, vol 1, issue 1, 2016 33 
10. Dorsch H, Jurock A E, Schoepe S, et al. 2015, 
Grants4Targets — an open innovation initiative to foster 
drug discovery collaborations between academia and the 
pharmaceutical industry. Nature Reviews Drug Discov-
ery, vol.14: 74–76.  
11. Schmitz A A, Hackethal S, Schulz A, et al. 2015, Phar-
ma compound sharing with academia: experiences with 
providing Vitamin D receptor ligands. Nature Reviews 
Drug Discovery, vol.14: 294–296.  
12. Asadullah K, Busch A, Gottwald G, et al. 2015, Indus-
trial–academic collaborations for biomarkers. Nature 
Reviews Drug Discovery, vol.14: 805–806. 
13. Wholley D, 2014, The biomarkers consortium. Nature 
Reviews Drug Discovery, vol.13: 791–792. 
14. Stephenson D, Sauer J M, 2014, The predictive safety 
testing consortium and the coalition against major dis-
eases. Nature Reviews Drug Discovery, vol.13: 793–794. 
15. Lessl M, Douglas F, 2010, From technology-transfer to 
know-how interchange. Wissenschaftsmanagement, vol.(2): 
34–41. 
 
 
